Molecular structure of SMCC, CAS Number: 64987-85-5
SMCC (CAS 64987-85-5)
Alternate Names:
N-Succinimidyl 4-(Maleimidomethyl)cyclohexane-1-carboxylate
Application:
SMCC is a heterobifunctional sulfhydryl- and amine- reactive crosslinker, 11.6 Angstrom spacer arm
CAS Number:
64987-85-5
Molecular Weight:
334.32
Molecular Formula:
C16H18N2O6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
SMCC, also known as N-Succinimidyl 4-(Maleimidomethyl)cyclohexane-1-carboxylate, plays a functional role in bioconjugation and crosslinking processes. Its maleimide group interacts with thiol-containing molecules, such as cysteine residues in proteins, through a nucleophilic addition reaction. This interaction forms a stable covalent bond, known as a thioether linkage, which can be utilized to conjugate proteins, peptides, or other biomolecules for various applications. The cyclohexane-1-carboxylate moiety provides stability and solubility to the compound, allowing for efficient and specific conjugation reactions.
SMCC (CAS 64987-85-5) References
- Antibody-maytansinoid conjugates designed to bypass multidrug resistance. | Kovtun, YV., et al. 2010. Cancer Res. 70: 2528-37. PMID: 20197459
- Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. | Jackson, D. and Stover, D. 2015. Pharm Res. 32: 3458-69. PMID: 25339341
- Antibodies and associates: Partners in targeted drug delivery. | Kennedy, PJ., et al. 2017. Pharmacol Ther. 177: 129-145. PMID: 28315359
- DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. | Takegawa, N., et al. 2017. Int J Cancer. 141: 1682-1689. PMID: 28677116
- Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. | Dan, N., et al. 2018. Pharmaceuticals (Basel). 11: PMID: 29642542
- Fabrication of magnetic nanochains linked with CTX and curcumin for dual modal imaging detection and limitation of early tumour. | Yang, Y., et al. 2018. Cell Prolif. 51: e12486. PMID: 30133050
- An Antibody-like Polymeric Nanoparticle Removes Intratumoral Galectin-1 to Enhance Antitumor T-Cell Responses in Cancer Immunotherapy. | Gu, Y., et al. 2021. ACS Appl Mater Interfaces. 13: 22159-22168. PMID: 33955217
- Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. | Sheyi, R., et al. 2022. Pharmaceutics. 14: PMID: 35214128
- Drug conjugate-based anticancer therapy - Current status and perspectives. | Yang, Y., et al. 2023. Cancer Lett. 552: 215969. PMID: 36279982
- Hemoglobin–Albumin Clusters Prepared Using N-Succinimidyl 3-Maleimidopropionate as an Appropriate Cross-Linker | Ryosuke Funaki, Tomonori Kashima, Wataru Okamoto, Sho Sakata, Yoshitsugu Morita, Masayo Sakata, and Teruyuki Komatsu*. 2019. ACS Omega. 4, 2: 3228–3233.
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SMCC, 25 mg | sc-212277 | 25 mg | $75.00 | |||
SMCC, 100 mg | sc-212277A | 100 mg | $165.00 | |||
SMCC, 1 g | sc-212277B | 1 g | $347.00 |